Published in Neurosci Lett on December 09, 2011
Choosing an animal model for the study of Huntington's disease. Nat Rev Neurosci (2013) 1.47
BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. Transl Psychiatry (2013) 1.02
Adult neurogenesis in neurodegenerative diseases. Cold Spring Harb Perspect Biol (2015) 0.96
Hippocampal neurogenesis, cognitive deficits and affective disorder in Huntington's disease. Neural Plast (2012) 0.91
Dysfunctional behavioral modulation of corticostriatal communication in the R6/2 mouse model of Huntington's disease. PLoS One (2012) 0.91
A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice. PLoS One (2013) 0.89
A Longitudinal Operant Assessment of Cognitive and Behavioural Changes in the HdhQ111 Mouse Model of Huntington's Disease. PLoS One (2016) 0.89
Physical exercise-induced adult neurogenesis: a good strategy to prevent cognitive decline in neurodegenerative diseases? Biomed Res Int (2014) 0.87
Differential effects of early environmental enrichment on emotionality related behaviours in Huntington's disease transgenic mice. J Physiol (2012) 0.86
Mood disorders in Huntington's disease: from behavior to cellular and molecular mechanisms. Front Behav Neurosci (2014) 0.86
HD iPSC-derived neural progenitors accumulate in culture and are susceptible to BDNF withdrawal due to glutamate toxicity. Hum Mol Genet (2015) 0.85
A Tale of Two Maladies? Pathogenesis of Depression with and without the Huntington's Disease Gene Mutation. Front Neurol (2013) 0.83
Expression of mutant huntingtin in leptin receptor-expressing neurons does not control the metabolic and psychiatric phenotype of the BACHD mouse. PLoS One (2012) 0.79
Progressive Cl- channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington's mice. J Gen Physiol (2016) 0.78
A Longitudinal Motor Characterisation of the HdhQ111 Mouse Model of Huntington's Disease. J Huntingtons Dis (2016) 0.77
Huntingtin acts non cell-autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse. PLoS One (2013) 0.76
Metabolic and behavioral effects of mutant huntingtin deletion in Sim1 neurons in the BACHD mouse model of Huntington's disease. Sci Rep (2016) 0.75
Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes. Hum Mol Genet (2016) 0.75
Ablation of hippocampal neurogenesis impairs contextual fear conditioning and synaptic plasticity in the dentate gyrus. Proc Natl Acad Sci U S A (2006) 5.83
Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell (2004) 5.67
Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron (2009) 5.20
Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation. J Neurosci (2007) 3.79
Chronic fluoxetine stimulates maturation and synaptic plasticity of adult-born hippocampal granule cells. J Neurosci (2008) 3.13
Subunit composition of functional nicotinic receptors in dopaminergic neurons investigated with knock-out mice. J Neurosci (2003) 2.85
5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants. Neuron (2010) 2.75
The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell (2002) 2.56
Huntingtin is required for mitotic spindle orientation and mammalian neurogenesis. Neuron (2010) 2.54
Vesicular glycolysis provides on-board energy for fast axonal transport. Cell (2013) 2.33
Identifying polyglutamine protein species in situ that best predict neurodegeneration. Nat Chem Biol (2011) 2.24
Huntingtin phosphorylation acts as a molecular switch for anterograde/retrograde transport in neurons. EMBO J (2008) 2.03
Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease. J Clin Invest (2011) 1.79
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase. J Clin Invest (2006) 1.44
Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol (2008) 1.40
VGLUT3 (vesicular glutamate transporter type 3) contribution to the regulation of serotonergic transmission and anxiety. J Neurosci (2010) 1.29
Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet (2008) 1.28
Serotonin-1A autoreceptors are necessary and sufficient for the normal formation of circuits underlying innate anxiety. J Neurosci (2011) 1.27
Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci (2005) 1.27
Increased fear response to contextual cues in mice lacking the 5-HT1A receptor. Neuropsychopharmacology (2006) 1.24
Phosphorylation of huntingtin by cyclin-dependent kinase 5 is induced by DNA damage and regulates wild-type and mutant huntingtin toxicity in neurons. J Neurosci (2007) 1.20
Insm1 (IA-1) is a crucial component of the transcriptional network that controls differentiation of the sympatho-adrenal lineage. Development (2007) 1.20
Transcriptional repression coordinates the temporal switch from motor to serotonergic neurogenesis. Nat Neurosci (2007) 1.17
Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421. J Neurosci (2006) 1.16
The serum- and glucocorticoid-induced kinase SGK inhibits mutant huntingtin-induced toxicity by phosphorylating serine 421 of huntingtin. Eur J Neurosci (2004) 1.15
Local cholesterol increase triggers amyloid precursor protein-Bace1 clustering in lipid rafts and rapid endocytosis. FASEB J (2011) 1.12
Elongator - an emerging role in neurological disorders. Trends Mol Med (2009) 1.10
Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress. Behav Brain Res (2009) 1.08
Interplay of beta2* nicotinic receptors and dopamine pathways in the control of spontaneous locomotion. Proc Natl Acad Sci U S A (2008) 1.08
Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease. Proc Natl Acad Sci U S A (2003) 1.05
Brain-derived neurotrophic factor-deficient mice exhibit a hippocampal hyperserotonergic phenotype. Int J Neuropsychopharmacol (2007) 1.01
Implications of the functional integration of adult-born hippocampal neurons in anxiety-depression disorders. Neuroscientist (2010) 1.00
pARIS-htt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular trafficking. Mol Brain (2010) 1.00
Insm1 (IA-1) is an essential component of the regulatory network that specifies monoaminergic neuronal phenotypes in the vertebrate hindbrain. Development (2009) 0.98
Phosphorylation of arfaptin 2 at Ser260 by Akt Inhibits PolyQ-huntingtin-induced toxicity by rescuing proteasome impairment. J Biol Chem (2005) 0.97
Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol Brain (2009) 0.96
Mutant Huntingtin alters retrograde transport of TrkB receptors in striatal dendrites. J Neurosci (2013) 0.96
In vivo calpain/caspase cross-talk during 3-nitropropionic acid-induced striatal degeneration: implication of a calpain-mediated cleavage of active caspase-3. J Biol Chem (2003) 0.96
The ataxia-ome: connecting disease proteins of the cerebellum. Cell (2006) 0.95
Modeling treatment-resistant depression. Neuropharmacology (2011) 0.93
Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. Int J Neuropsychopharmacol (2009) 0.92
Serotonin transporter oligomerization documented in RN46A cells and neurons by sensitized acceptor emission FRET and fluorescence lifetime imaging microscopy. Biochem Biophys Res Commun (2009) 0.92
Alpha7-nicotinic receptors modulate nicotine-induced reinforcement and extracellular dopamine outflow in the mesolimbic system in mice. Psychopharmacology (Berl) (2011) 0.91
Antidepressant and anxiolytic potential of the multimodal antidepressant vortioxetine (Lu AA21004) assessed by behavioural and neurogenesis outcomes in mice. Neuropharmacology (2013) 0.90
Altered cholesterol homeostasis contributes to enhanced excitotoxicity in Huntington's disease. J Neurochem (2010) 0.89
Modification of Mecp2 dosage alters axonal transport through the Huntingtin/Hap1 pathway. Neurobiol Dis (2011) 0.89
A longitudinal study of 5-HT outflow during chronic fluoxetine treatment using a new technique of chronic microdialysis in a highly emotional mouse strain. Eur J Pharmacol (2009) 0.89
Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone administration. Mol Pharmacol (2011) 0.87
Influence of brain-derived neurotrophic factor (BDNF) on serotonin neurotransmission in the hippocampus of adult rodents. Eur J Pharmacol (2008) 0.87
Blockade of 5-HT1A receptors by (+/-)-pindolol potentiates cortical 5-HT outflow, but not antidepressant-like activity of paroxetine: microdialysis and behavioral approaches in 5-HT1A receptor knockout mice. Neuropsychopharmacology (2006) 0.87
Effect of the alpha4beta2* nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area. Neuropharmacology (2009) 0.87
Characterization of 5-HT(1A/1B)-/- mice: an animal model sensitive to anxiolytic treatments. Neuropharmacology (2011) 0.87
Ventral hippocampal molecular pathways and impaired neurogenesis associated with 5-HT₁A and 5-HT₁B receptors disruption in mice. Neurosci Lett (2012) 0.86
Releasing the brake: restoring fast axonal transport in neurodegenerative disorders. Trends Cell Biol (2013) 0.86
Huntingtin's function in axonal transport is conserved in Drosophila melanogaster. PLoS One (2013) 0.85
Improved efficacy of fluoxetine in increasing hippocampal 5-hydroxytryptamine outflow in 5-HT(1B) receptor knock-out mice. Eur J Pharmacol (2002) 0.84
Serotonin1B heteroreceptor activation induces an antidepressant-like effect in mice with an alteration of the serotonergic system. J Psychiatry Neurosci (2008) 0.84
The monoaminergic tripartite synapse: a putative target for currently available antidepressant drugs. Curr Drug Targets (2013) 0.84
Increasing membrane cholesterol of neurons in culture recapitulates Alzheimer's disease early phenotypes. Mol Neurodegener (2014) 0.83
Consequences of changes in BDNF levels on serotonin neurotransmission, 5-HT transporter expression and function: studies in adult mice hippocampus. Pharmacol Biochem Behav (2007) 0.83
Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol (2007) 0.82
Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice. Br J Pharmacol (2013) 0.82
Blockade of substance P (neurokinin 1) receptors enhances extracellular serotonin when combined with a selective serotonin reuptake inhibitor: an in vivo microdialysis study in mice. J Neurochem (2004) 0.82
Antinociceptive effects of fluoxetine in a mouse model of anxiety/depression. Neuroreport (2012) 0.81
Huntingtin mediates anxiety/depression-related behaviors and hippocampal neurogenesis. J Neurosci (2013) 0.81
A method for biomarker measurements in peripheral blood mononuclear cells isolated from anxious and depressed mice: β-arrestin 1 protein levels in depression and treatment. Front Pharmacol (2013) 0.80
Activation of IGF-1 and insulin signaling pathways ameliorate mitochondrial function and energy metabolism in Huntington's Disease human lymphoblasts. Mol Neurobiol (2014) 0.80
Axonal transport failure in neurodegenerative disorders: the case of Huntington's disease. Pathol Biol (Paris) (2005) 0.79
[Huntington's disease: intracellular signaling pathways and neuronal death]. J Soc Biol (2005) 0.79
5-HT2 ligands in the treatment of anxiety and depression. Expert Opin Investig Drugs (2012) 0.77
Microdialysis approach to study serotonin outflow in mice following selective serotonin reuptake inhibitors and substance P (neurokinin 1) receptor antagonist administration: a review. Curr Drug Targets (2006) 0.77
Serine 421 regulates mutant huntingtin toxicity and clearance in mice. J Clin Invest (2016) 0.76
Sustained pharmacological blockade of NK1 substance P receptors causes functional desensitization of dorsal raphe 5-HT 1A autoreceptors in mice. J Neurochem (2005) 0.76
Serotonin transporter in substance P (neurokinin 1) receptor knock-out mice. Eur J Pharmacol (2004) 0.76
Huntingtin acts non cell-autonomously on hippocampal neurogenesis and controls anxiety-related behaviors in adult mouse. PLoS One (2013) 0.76
[Unexpected link between Huntington disease and Rett syndrome]. Med Sci (Paris) (2012) 0.76
Toward cell specificity in SCA1. Neuron (2002) 0.75
Interest of using genetically manipulated mice as models of depression to evaluate antidepressant drugs activity: a review. Fundam Clin Pharmacol (2009) 0.75